Healthcare products company West Pharmaceutical Services (NYSE:WST) reported Q4 CY2024 results topping the market’s revenue expectations , with sales up 2.3% year on year to $748.8 million. On the other hand, the company’s full-year revenue guidance of $2.89 billion at the midpoint came in 5% below analysts’ estimates. Its non-GAAP profit of $1.82 per share was 5.3% above analysts’ consensus estimates.
https://finance.yahoo.com/news/west-pharmaceutical-services-nyse-wst-110535763.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.